Results from two Amgen studies on Lumakras for lung cancer showed its ability to slow disease progression, although combining it with immunotherapy increased the risk for TRAEs.
/PRNewswire/ Amgen (NASDAQ: AMGN) today announced three new data sets from its thoracic oncology portfolio that will be presented at the International.
Today, Sarah Cannon Research Institute announced that it will highlight its latest cancer research insights through more than 140 abstracts and presentations at the 2022 American Society of Clinical